-
American Association for Cancer Research
The American Association for Cancer Research (AACR) recently awarded $480,000 to four Dana-Farber physician-scientists who are investigating new methods of prevention, diagnosis, and treatment for various types of cancers. As the first cancer research organization dedicated to preventing and curing cancer, AACR is a long-standing partner in Dana-Farber’s mission to defy cancer.
-
American Federation for Aging Research
The Glenn Foundation for Medical Research and the American Federation for Aging Research awarded a $300,000 grant to support basic science research by Dana-Farber’s Edward Chouchani, PhD, as he seeks to systematically define the functional targets of reactive oxygen species that contribute to longevity and age.
-
Richard and Sandra Bornstein
Sandra Bornstein and her late husband, Richard, made a generous commitment of $400,000 to support early career physician-scientists on the leukemia and stem cell transplant teams at Dana-Farber. Faculty excellence is a top priority of The Dana-Farber Campaign, and this funding will help fuel the growth of promising investigators as they work to ensure greater numbers…
-
Clifford Family
The Clifford Family established the Woolley-Clifford Foundation Fund with a $100,000 gift, supporting the research of David Kozono, MD, PhD, as he works to investigate blood and tissue-based biomarkers in lung cancer patients that can help predict lung inflammation and anti-tumor response following radiation therapy.
-
Harold and Janice Cohen Foundation
The Harold and Janice Cohen Foundation made a generous $150,000 gift in support of lifelong friend Richard M. Stone, MD, the Lunder Family Chair in Leukemia at Dana-Farber. The gift will advance Stone’s research to identify novel targets in acute leukemia and myelodysplastic syndromes.
-
Colorectal Cancer Alliance
The Colorectal Cancer Alliance made a $150,000 grant to Dana-Farber to fund research into new treatments for colorectal cancer, the third most common type of cancer worldwide. Building on previous research, a Dana-Farber team is working to develop a novel class of therapeutics designed to promote cancer cell death by inducing cancer cell maturation.
-
Conquer Cancer
Conquer Cancer,® the ASCO Foundation, awarded $100,000 worth of grants to support studies addressing cancer care disparities in clinical trial enrollment for pediatric patients, and exploring new treatment options for prostate cancer that can reduce the chance of recurrence.
-
The Dana Foundation
Our historic partner, the Dana Foundation, made a new $100,000 commitment to the Defy Cancer Fund, which provides unrestricted support for The Dana-Farber Campaign. These flexible funds propel innovative early stage research, speed new drugs into clinical trials, retain and attract top talent; meet unanticipated needs; and ensure that we are fully serving our patients’…
-
Friends of Dana-Farber Annual Gala
The Friends of Dana-Farber Cancer Institute recently held their Annual Gala, raising more than $465,000. Evening with Friends featured cocktails, dinner, and a live auction. The Friends exemplify the “power of friends” through their dual mission: raising funds to support research, patient services, breast and gynecologic cancer programs, and oncology fellowships; and providing services that…
-
Gastric Cancer Foundation
The Gastric Cancer Foundation gave $100,000 to support the research of Dana-Farber’s Nilay Sethi, MD, PhD, who is investigating treatments for gastric cancers with homologous recombination (HR) deficiencies that have proven effective in other types of HR-deficient cancers.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.